The role of Kupffer cells in the hepatic response to silver nanoparticles

Nanotoxicology

Volumn 8, Issue SUPPL. 1, 2014, Pages 149-154

  Kermanizadeh, Ali ^a,b,c   Chauché, Caroline ^b,c   Balharry, Dominique ^a   Brown, David M ^a   Kanase, Nilesh ^a   Boczkowski, Jorge ^b,c,d,e   Lanone, Sophie ^b,c,d   Stone, Vicki ^a  

^a HERIOT WATT UNIVERSITY   (United Kingdom)

^b UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^c FACULTÉ DE MÉDECINE   (France)

^d CENTRE HOSPITALIER INTERCOMMUNAL DE CRÉTEIL   (France)

^e HENRI MONDOR HOSPITAL   (France)

Author keywords

Ag NPs; Inflammatory response; Kupffer cells; Liver; Liver function

Indexed keywords

ALBUMIN; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 4; SILVER NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA; METAL NANOPARTICLE; SILVER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL POPULATION; CELL PROTECTION; CONTROLLED STUDY; CYTOKINE RELEASE; FEMALE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KUPFFER CELL; LIVER FUNCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; UPREGULATION; ANIMAL; C57BL MOUSE; CHEMISTRY; MALE; PHYSIOLOGY;

ANIMALS; FEMALE; KUPFFER CELLS; MALE; METAL NANOPARTICLES; MICE; MICE, INBRED C57BL; SILVER;

EID: 84905963908     PISSN: 17435390     EISSN: 17435404     Source Type: Journal    
DOI: 10.3109/17435390.2013.866284     Document Type: Article

References (39)

1. Baffy G. 2009. Kupffer cells in non-alcoholic fatty liver disease: the emerging view. J Hepatol 51: 212-23.
2. Bottcher JP, Knolle PA, Stabenow D. 2011. Mechanisms balancing tolerance and immunity in the liver. Dig Dis 29: 384-90.
3. Buzea C, Pacheco II, Robbie K. 2007. Nanomaterials and nanoparticles: sources and toxicity. Biointerpahses 2: 18-67.
4. Chen C, Zhang P, Hou X, Chai Z. 1999. Sub-cellular distribution of selenium and Se-containing proteins in human liver. Biochem Biophys Acta Gen Subjects 1427: 205-15.
5. Crispin JC, Tsokos GC. 2009. Transcriptional regulation of IL-2 in health and autoimmunity. Autoimmun Rev 8: 190-5.
6. Cullen JM, Faiola B, Melich DH, Peterson RA, Jordan HL, Kimbrough CL, et al. 2013. Effects of Kupffer cell depletion on acute alphanaphthylisothiocyante induced liver toxicity in male mice. Toxicol Pathol 41: 7-17.
7. Diesen DL, Kuo PC. 2009. Nitric oxide and redox regulation in the liver: Part I. General considerations and redox biology in hepatitis. J Surg Res 162: 95-109.
8. Filippi C, Kermanizadeh A, Stone V. 2014. Kupffer cell contribution to the hepatic response to nanomaterials, in preparation.
9. Gaiser BK, Hirn S, Kermanizadeh A, Kanase N, Fytianos K, Wenk A, et al. 2013. Effects of silver nanoparticles on the liver and hepatocytes in vitro. Toxicol Sci 131(2): 537-47.
10. Geiser M, Kreyling WG. 2010. Deposition and biokenetics of inhaled nanoparticles. Part Fibre Toxicol 7: 2-19.
11. Hoet PHM, Hohlfeld IB, Salata O. 2004. Nanoparticles - known and unknown health risks. J Nanobiotechnol 2: 12-27.
12. Jacobsen NR, Pojano G, Wallin H, Jensen KA. 2010. Nanomaterial dispersion protocol for toxicological studies in ENPRA. Internal ENPRA Project Report. The National Research Centre for the Working Environment. Available on request.
13. Johnston H, Brown D, Kermanizadeh A, Gubbins E, Stone V. 2012. Investigating the relationship between nanomaterial hazard and physicochemical properties: informing the exploitation of nanomaterials within therapeutic and diagnostic applications. J Control Release 164(3): 307-13.
14. Kermanizadeh A, Brown DM, Hutchison G, Stone V. 2013a. Engineered nanomaterial impact in the liver following exposure via an intravenous route - the role of polymorphonuclear leukocytes and gene expression in the organ. Nanomed Nanotechnol 4: 157.
15. Kermanizadeh A, Gaiser BK, Hutchison GR, Stone V. 2012. An in vitro liver model - assessing oxidative stress and genotoxicity following exposure of hepatocytes to a panel of engineered nanoparticles. Part Fibre Toxicol 9: 28.
16. Kermanizadeh A, Gaiser BK, Ward MB, Stone V. 2013b. Primary human hepatocytes vs. hepatic cell line - assessing their suitability for in vitro nanotoxicology. Nanotoxicology 7: 1255-71.
17. Kermanizadeh A, Pojana G, Gaiser BK, Birkedal R, Bilaničová D, Wallin H, et al. 2013c. In vitro assessment of engineered nanomaterials using C3A cells: cytotoxicity, pro-inflammatory cytokines and function markers. Nanotoxiocology 7: 301-13.
18. Kmiec Z. 2001. Co-operation of liver cells in health and disease. Adv Anat Embryol Cell Biol 161: 1-151.
19. Li SX, Li B, Jiang HR, Wang Y, Qu ML, Duan HY, et al. 2013. Macrophage depletion impairs corneal wound healing after autologous transplantation in mice. PLoS One 8: 4.
20. Lipka J, Semmler-Behnke M, Sperling RA, Wenk A, Takenaka S, Schleh C, et al. 2010. Bio-distribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection. Biomaterials 31: 6574-81.
21. Mocellin S, Panelli MC, Wang E, Nagorsen D, Marincola FM. 2004. The dual role of IL10. Trends Immunol 24: 36-43.
22. Moelants EAV, Mortier A, Van Damme J, Proost P. 2013. Regulation of TNF-alpha with a focus on rheumatoid arthritis. Immunol Cell Biol 91: 393-401.
23. Moore KW, Malefyt R, Coffman RL, O'Garra A. 2001. Interluekin-10 and the interluekin-10 receptor. Annu Rev Immunol 19: 683-765.
24. Nemeth E, Baird AW, O'Farrelly C. 2009. Microanatomy of the liver immune system. Semin Immunopathol 31: 333-43.
25. Novak ML, Koh TJ. 2013. Macrophage phenotypes during tissue repair. J Leukocyte Biol 93: 875-81.
26. Oberdorster G, Stone V, Donaldson K. 2007. Toxicology of nanoparticles: a historical perspective. Nanotoxicology 1: 2-25.
27. Papp T, Schiffmann D, Weiss D, Castronova V, Vallyathan V, Rahman Q. 2008. Human health implications of nonmaterial exposure. Nanotoxicology 2: 9-27.
28. Pillai MR, Bix M. 2011. Evolution of IL4 and pathogen antagonism. Growth Factors 29: 153-60.
29. Sadauskas E, Jacobson NR, Danscher G, Soltenberg M, Larsen A, Kreyling W, Wallin H. 2009. Bio-disruption of gold nanoparticles in mouse lung following intratracheal instillation. Chem Central J 3: 16-23.
30. Seki A, Sakai Y, Komura T, Higashimoto M, Fujinaga H, Honda M, et al. 2012. Therapeutic effect of adipose derived mesenchymal stem cell to murine NASH liver cirrhosis inactivating Kupffer/Macrophage and helper T cell. Hepatology 56: S1101A.
31. Semmler-Behnke M, Wolfgang KG, Lipka J, Fertsch S, Wenk A, Takeneka S, et al. 2008. Bio-distribution of 1.4 and 18 nm gold particles in rats. Small 12: 2108-11.
32. Sharma A, Madhunapantula SV, Robertson GP. 2012. Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opin Drug Metab Toxicol 8(1): 47-69.
33. Shrivastava S, Bera T, Singh SK, Singh G, Ramachandrarao P, Dash D. 2009. Characterization of anti-platelet properties of silver nanoparticles. ACS Nano 3(6): 1357-64.
34. Singh RP, Ramarao P. 2012. Cellular uptake, intracellular trafficking and cytotoxicity of silver nanoparticles. Toxicol Lett 213: 249-59.
35. Swenson-Fields KI, Vivian CJ, Salah SM, Peda JD, Davis BM, van Rooijen N, et al. 2013. Macrophage promote polycystic kidney disease progression. Kidney Int 83: 855-64.
36. Tiegs G, Lohse AW. 2009. Immune tolerance: what is unique about the liver. J Autoimmun 34: 1-6.
37. van der Zande M, Vandebriel RJ, Van Doren E, Kramer E, Herrera Rivera Z, Serrano-Rojero CS, et al. 2012. Distribution, elimination, and toxicity of silver nanoparticles and silver ions in rats after 28 day oral exposure. ACS Nano 6: 7427-42.
38. Walczyk D, Bombelli FB, Monopoli MP, Lynch I, Dawson KA. 2010. What the cell ''sees'' in bionanoscience. J Am Chem Soc 132: 5761-8.
39. Woodrow Wilson. Available from: http://www.nanotechproject.org/inven tories/consumer/browse/products/. Accessed on 14 February 2013.